ReviewThe Lancet. Infectious diseases2022
The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations.
Review in The Lancet. Infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Operational complexities in international clinical trials: a systematic review of challenges and proposed solutions.BMJ open · 2024Pooled it
- A rapid review of community engagement and informed consent processes for adaptive platform trials and alternative design trials for public health emergencies.Wellcome open research · 2023Pooled it
- Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.The New England journal of medicine · 2026Trial
- Towards broader-spectrum direct-acting antivirals against RNA viruses.Nature reviews. Microbiology · 2026Review
- A scoping review of randomized controlled trials in the early phase of the COVID-19 pandemic: country-level research response to COVID-19 therapeutics and vaccines.BMC infectious diseases · 2026Article
- Logistical Challenges in Platform Randomized Trials - Operational Realities That Curb the Promise of Efficiency.Clinical epidemiology · 2026Article
- Approval delays in multi-country COVID-19 trials: the case of COPCOV and the risk of therapeutic inertia.Trials · 2025Article
- Benefits of group sequential design and sample size re-estimation for randomised controlled trials evaluating the prevention of ventilator-associated pneumonia: a simulation study informed by real world data.BMC medical research methodology · 2025Article
- Health research versus the virus: strengthening systems, saving lives.Health research policy and systems · 2025Article
- Principal investigators' experience of COVID-19 therapeutic clinical trials in Japan: a qualitative study.BMJ open · 2025Article
- Democratising clinical trials research to strengthen primary health care.The Lancet. Global health · 2025Review
- Review
- Establishing clinical research networks for future infectious disease outbreak responses in Southeast Asia: Report of a workshop on challenges and opportunities.IJID regions · 2025Review
- Democratising the design and delivery of large-scale randomised, controlled clinical trials in primary care: A personal view.The European journal of general practice · 2024Article
- Innovative approaches for vaccine trials as a key component of pandemic preparedness - a white paper.Infection · 2024Review
- Article
- The DAWN antivirals trial: process evaluation of a COVID-19 trial in general practice.BJGP open · 2024Article
- Coordination of COVID-19 platform trials in Europe.Trials · 2024Article
- Clinical trials and their impact on policy during COVID-19: a review.Wellcome open research · 2024Review
- Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies.Virology journal · 2023Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinicians have worked feverishly to treat patients with COVID-19 while also carrying out clinical research studies. We discuss how the clinical research community responded to the pandemic in Europe, what lessons were learned, and provide recommendations for future clinical research response during pandemics. We focused on two platform trials: RECOVERY and REMAP-CAP. Both trials were able to enrol patients very rapidly during the beginning of the pandemic because of pre-established structures and procedures, and because they share simple execution and flexibility to adjust when evidence emergences. However, contracting, regulatory hurdles, and competition with (often inadequately designed or underpowered) national trials was a major challenge in several EU countries. We recommend the creation of structures and partnerships that facilitate prioritisation of clinical research, simplification of clinical trial delivery, development of digital models and procedures for data collection and sharing, development of a mechanism to rapidly leverage pandemic funding and to connect EU funding with national funding, and investment in clinical trial networks, platform trials, and master protocols. Finally, the future pandemic clinical research response of the EU should be embedded in the global response. We believe that globally connected clinical trial networks will be essential to respond more effectively to future infectious diseases outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.